Sign Out
Gefitinib is indicated as first-line monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.
Gefitinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously received chemotherapy (see Precautions).
Continue with Google